CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.

CONCLUSIONS.—: NLPHL can lack CD20 de novo without prior rituximab therapy. In such cases, extensive immunophenotyping helps distinguish NLPHL from lymphocyte-rich classic Hodgkin lymphoma, which differ in clinical behavior and therapy. In our series, CD20-negative NLPHL showed both classic and variant histologic patterns and the expected range of clinical behavior seen in NLPHL, including 1 case with suspected large cell transformation.
PMID: 32991677 [PubMed - as supplied by publisher]

Source: Archives of Pathology and Laboratory Medicine - September 28, 2020 Category: Laboratory Medicine Authors: Menke JR, Spinner MA, Natkunam Y, Warnke RA, Advani RH, Gratzinger DA Tags: Arch Pathol Lab Med Source Type: research